Bioenvision Provides Evoltra Regulatory Update

Bioenvision announced an update on the status of its Marketing Authorization Application to the European Medicines Evaluation Agency (EMEA) to include a new indication for Evoltra (clofarabine) for the treatment of acute myeloid leukemia (AML) in elderly patients who have one or more of the following: adverse cytogenetics, secondary AML, ≥ 70 years old or significant co-morbidities and are therefore not considered suitable for intensive chemotherapy.
Bioenvision